D609
Based on 8 publication(s) in Google Scholar
D609, an antitumoural xanthate, is a specific and competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor with a Ki of 6.4 μM. D609 is an antioxidative protector and has antiviral and anti-inflammatory activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.0%
- CAS No.: 83373-60-8
- Formule: C11H15KOS2
- Masse moléculaire:266.46
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Lipid Metabolism Compound Library
HY-L091
-
Targeted Diversity Library
HY-L099
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) D609
More- Adv Sci (Weinh). 2023 Sep;10(25):e2206238. [Abstract]
- Int J Mol Sci. 2025 Jul 30;26(15):7361. [Abstract]
- J Physiol Biochem. 2022 May;78(2):355-363. [Abstract]
- Bioorg Med Chem. 2015 Sep 15;23(18):6173-84. [Abstract]
- Traffic. 2015 May;16(5):476-92. [Abstract]
- Thromb J. 2021 Apr 28;19(1):27. [Abstract]
- Curr Eye Res. 2025 Jun 24:1-9. [Abstract]
- Patent. US20230050888A1.
Customer Validation & Images
-
WB
-
Bio/Physico-chemical Assay
-
WB
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
Voir tous les produits spécifiques à Isoform Phospholipase
More
Activité biologique
Ki: 6.4 μM (PC-PLC)
D609 (100 μM; for 2 h) significantly attenuats the proliferation of various cell lines[2].
D609 (50, 100 and 200 μM; for 2 h) results in caspase-3 activation with 200 μM and causes no detectable cleavage with 50, 100 μM[2].
D609 (100 μM; for 2 h) significantly inhibits BrdU incorporation in BV-2 microglia and causes accumulation of cells in G1 phase with decreased number of cells in the S phase[2].
D609 (100 μM; for 2 h and cultured for an additional 2 h or 22 h without D609) increases ceramide levels, up-regulates p21 expression and causes a decreases in phospho-Rb[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW 264.7 macrophages, N9 and BV-2 microglia, and DITNC1 astrocytes
-
Concentration:100 μM
-
Incubation Time:For 2 hours
-
Result:Significantly attenuated the proliferation of RAW 264.7 macrophages, N9 and BV-2 microglia, and DITNC1 astrocytes, without affecting cell viability.
-
Cell Line:BV-2 cells
-
Concentration:50, 100 and 200 μM
-
Incubation Time:For 2 hours
-
Result:Activated caspase-3 in a dose- and time-dependent manner.
-
Cell Line:BV-2 cells
-
Concentration:100 μM
-
Incubation Time:For 2 hours
-
Result:Significantly inhibited BrdU incorporation in BV-2 microglia and caused accumulation of cells in G1 phase with decreased number of cells in the S phase.
-
Cell Line:BV-2 cells
-
Concentration:100 μM
-
Incubation Time:For 2 hours
-
Result:Increased ceramide levels, up-regulated p21 expression and causes a decreased in phospho-Rb.
D609 (50 mg/kg; ip; single dose) for 30 min before intratracheal administration of LPS (3 mg/kg) prevents the development of LPS-induced pulmonary hypertension in adult male Wistar rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:26-week-old apoE−/− and C57BL/6 WT mice[3]
-
Dosage:2.5, 10 mg/kg
-
Administration:IP; per day for 6 weeks
-
Result:Inhibited the progression of preexisting atherosclerotic lesions in apoE−/− mice and changed the lesion composition into a more stable phenotype.
Significantly decreased the aortic endothelial expression of the vascular cell adhesion molecule-1 and the intercellular adhesion molecule-1.
Chemical Information
-
CAS No. 83373-60-8
-
Appearance Solid
-
Masse moléculaire 266.46
-
Formule C11H15KOS2
-
Color White to off-white
-
SMILES
S=C(OC1C2C3CCCC3C(C1)C2)S[K]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
2023 Sep;10(25):e2206238. PMID: 37400423 -
Int J Mol Sci
Direct and Indirect Downstream Pathways That Regulate Repulsive Guidance Effects of FGF3 on Developing Thalamocortical Axons. [Abstract]2025 Jul 30;26(15):7361. PMID: 40806490 -
J Physiol Biochem
D609 inhibition of phosphatidylcholine-specific phospholipase C attenuates prolonged insulin stimulation-mediated GLUT4 downregulation in 3T3-L1 adipocytes. [Abstract]2022 May;78(2):355-363. PMID: 35048323
D609 purchased from MedChemExpress. Usage Cited in: J Physiol Biochem. 2022 May;78(2):355-363. [Abstract]
D609 (0, 50, 100, 200 μM; 30 min; insulin (500 nM) for 4 h) showed a weakened GLUT4 deficit in 3T3-L1 cells.
D609 purchased from MedChemExpress. Usage Cited in: J Physiol Biochem. 2022 May;78(2):355-363. [Abstract]
D609 (200 μM; 30 min; insulin (500 nM) for 4 h) showed an inhibitory effect on PC-PLC activity in 3T3-L1 cells in the membranes (a) and no effect in total lysate (b).
-
Bioorg Med Chem
Discovery, synthesis and biological evaluation of 2-(4-(N-phenethylsulfamoyl)phenoxy)acetamides (SAPAs) as novel sphingomyelin synthase 1 inhibitors. [Abstract]2015 Sep 15;23(18):6173-84. PMID: 26314925 -
Traffic
Trafficking of Acetyl-C16-Ceramide-NBD with Long-Term Stability and No Cytotoxicity into the Golgi Complex. [Abstract]2015 May;16(5):476-92. PMID: 25615589 -
Thromb J
The role of Sphingomyelin synthase 2 (SMS2) in platelet activation and its clinical significance. [Abstract]2021 Apr 28;19(1):27. PMID: 33910580
D609 purchased from MedChemExpress. Usage Cited in: Thromb J. 2021 Apr 28;19(1):27. [Abstract]
D609 (0, 10, 100 μM) weakened PLCγ/PI3K/Akt phosphorylation in human platelets after stimulated by thrombin (0.03 U/mL) in a dose-dependent manner.
D609 purchased from MedChemExpress. Usage Cited in: Thromb J. 2021 Apr 28;19(1):27. [Abstract]
D609 (0, 10, 30, 100 μM) started to show an inhibitory effect on aggregation at a concentration of 10 µM. The aggregation rate was further reduced by an increase in concentration to 30 µM; when the concentration was increased to 100 µM, thrombin- and collagen-induced platelet aggregation were almost completely blocked.
D609 purchased from MedChemExpress. Usage Cited in: Thromb J. 2021 Apr 28;19(1):27. [Abstract]
D609 (100 μM) significantly inhibited platelet spreading.
D609 purchased from MedChemExpress. Usage Cited in: Thromb J. 2021 Apr 28;19(1):27. [Abstract]
D609 (10, 100 μM; 0, 30, 40, 50, 60 min) had no significant effect on clot retraction at low-dose D609 (10 µM), high-dose D609 (100 µM) remarkably suppressed clot retraction.
-
Curr Eye Res
Kisspeptin Suppresses the Growth of Primary Pterygial Cells via Inhibiting Chemokine (C-X-C Motif) Ligands in Microenvironment. [Abstract]2025 Jun 24:1-9. PMID: 40555256 -
Solvant et solubilité
DMSO : 100 mg/mL (375.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 2 mg/mL (7.51 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3 mg/mL (11.26 mM); Clear solution
This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 3 mg/mL (11.26 mM); Clear solution
This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (93.82 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. E Amtmann, et al. The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drugs Exp Clin Res. 1996;22(6):287-94. [Content Brief]
[2]. Gusain A, et al. Anti-proliferative effects of tricyclodecan-9-yl-xanthogenate (D609) involve ceramide and cell cycle inhibition.Mol Neurobiol. 2012 Jun;45(3):455-64. Epub 2012 Mar 14. [Content Brief]
[3]. Lu Zhang, et al. D609 inhibits progression of preexisting atheroma and promotes lesion stability in apolipoprotein e-/- mice: a role of phosphatidylcholine-specific phospholipase in atherosclerosis. Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):411-8. [Content Brief]
[4]. Rachele Pandolfi, et al. Role of acid sphingomyelinase and IL-6 as mediators of endotoxin-induced pulmonary vascular dysfunction. Thorax. 2017 May;72(5):460-471. [Content Brief]
[5]. Kalluri HS, et al. D609 inhibits the proliferation of neural progenitor cells.Neuroreport. 2010 Jul 14;21(10):700-3. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.7529 mL | 18.7645 mL | 37.5291 mL | 93.8227 mL |
| 5 mM | 0.7506 mL | 3.7529 mL | 7.5058 mL | 18.7645 mL | |
| DMSO | 10 mM | 0.3753 mL | 1.8765 mL | 3.7529 mL | 9.3823 mL |
| 15 mM | 0.2502 mL | 1.2510 mL | 2.5019 mL | 6.2548 mL | |
| 20 mM | 0.1876 mL | 0.9382 mL | 1.8765 mL | 4.6911 mL | |
| 25 mM | 0.1501 mL | 0.7506 mL | 1.5012 mL | 3.7529 mL | |
| 30 mM | 0.1251 mL | 0.6255 mL | 1.2510 mL | 3.1274 mL | |
| 40 mM | 0.0938 mL | 0.4691 mL | 0.9382 mL | 2.3456 mL | |
| 50 mM | 0.0751 mL | 0.3753 mL | 0.7506 mL | 1.8765 mL | |
| 60 mM | 0.0625 mL | 0.3127 mL | 0.6255 mL | 1.5637 mL | |
| 80 mM | 0.0469 mL | 0.2346 mL | 0.4691 mL | 1.1728 mL | |
| 100 mM | 0.0375 mL | 0.1876 mL | 0.3753 mL | 0.9382 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
D609 Related Classifications
HY-70072 Related Classifications
Powered by Bioz